Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Leukemia 41Gastrointestinal Stromal Tumors 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Leukemia, Myeloid, Chronic-Phase 27Blast Crisis 13Neoplasms 10Neoplasm Metastasis 10Melanoma 10Brain Neoplasms 10Lung Neoplasms 9Prostatic Neoplasms 8Leukemia, Myeloid, Acute 8Gliosarcoma 8Glioblastoma 8Leukemia, Myeloid, Accelerated Phase 7Glioma 6Carcinoma, Non-Small-Cell Lung 6Sarcoma 5Philadelphia Chromosome 5Oligodendroglioma 5Recurrence 4Primary Myelofibrosis 4Polycythemia Vera 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Central Nervous System Neoplasms 4Breast Neoplasms 4Astrocytoma 4

Interventions

fludarabine phosphate 21Cyclophosphamide 20Peripheral Blood Stem Cell Transplantation 19Busulfan 16Tacrolimus 14Whole-Body Irradiation 12Methotrexate 12Mycophenolic Acid 11Cyclosporine 11Antilymphocyte Serum 10fludarabine 6Filgrastim 6peginterferon alfa-2a 5ruxolitinib 4Radiotherapy 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Decitabine 4Aspirin 4Stem Cell Transplantation 3Injections 3Cytogenetic Analysis 3Cytarabine 3Biopsy 3Azacitidine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3merphos 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocythemia, Essential × Imatinib Mesylate × Clear all
NCT00245128 2012-01-13

Imatinib Mesylate in Treating Patients With Myelofibrosis

OHSU Knight Cancer Institute

Phase 2 Terminated
10 enrolled 6 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡